{"id":103849,"date":"2026-06-09T17:04:44","date_gmt":"2026-06-09T17:04:44","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/103849\/"},"modified":"2026-06-09T17:04:44","modified_gmt":"2026-06-09T17:04:44","slug":"novo-nordisks-stock-stuck-in-a-death-cross-as-oral-wegovy-hits-3-million-scripts","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/103849\/","title":{"rendered":"Novo Nordisk\u2019s Stock Stuck in a Death Cross as Oral Wegovy Hits 3 Million Scripts"},"content":{"rendered":"

While Novo Nordisk\u2019s pipeline continues to churn out clinical wins, its share price tells a far grimmer story. The stock is trading around 49% below its 52-week high of \u20ac70.13, and a textbook death cross has formed on the chart. The disconnect between operational milestones and market sentiment has rarely been sharper.<\/p>\n

The oral version of Wegovy (semaglutide 25 mg) has raced past three million prescriptions since its US launch on January 5, 2026. The first million took twelve weeks; the next two million arrived in only ten weeks, averaging one script every five seconds. Crucially, more than 80% of patients had never taken a GLP-1 drug before \u2013 a sign of genuine new-user acquisition. However, a Medicare programme coming into effect on July 1, 2026 will cap monthly costs at $50 for eligible patients, supporting volume but squeezing margins.<\/p>\n

At the ADA congress in New Orleans, CEO Mike Doustdar laid out a strategy going far beyond weight loss. Novo Nordisk aims to position semaglutide as an agent that reduces the \u201cbiological age\u201d of the heart and kidneys. Experimental protein clocks suggested organ-protective effects, and the company is also exploring applications in aesthetic medicine, including skincare and hair loss. Post-hoc analyses of the SELECT study \u2013 involving over 17,000 patients \u2013 showed a 42% reduction in asthma events, a 52% lower risk of sleep apnoea complications, and an average systolic blood pressure drop of 5.48 mmHg.<\/p>\n

Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n

But the company\u2019s broad ambitions are running into stiff headwinds. Management has flagged a potential revenue decline of up to 13% this year, undershooting analyst expectations, and will cut US list prices for key semaglutide brands from January 2027. The moves underline persistent pricing pressure in the GLP-1 market.<\/p>\n

That pressure is largely coming from Eli Lilly. On the same day Novo Nordisk presented its data, Lilly unveiled phase 3 results for retatrutide showing up to 28% weight loss after 80 weeks. Its oral candidate, Foundayo, outperformed oral semaglutide in the Achieve-3 study on both blood sugar control and weight reduction. Novo Nordisk\u2019s own next-in-line candidate, CagriSema, met primary endpoints in phase 2 diabetes trials \u2013 HbA1c down 1.91%, weight down 14.2% \u2013 but an FDA decision is not expected until the fourth quarter of 2026.<\/p>\n

The stock\u2019s technical picture reinforces the gloom. At \u20ac35.92, shares are trading just below their 50-day moving average of \u20ac35.96. That average has fallen beneath the 200-day line, forming what technicians call a death cross \u2013 a classic confirmation of a long-term downtrend. The relative strength index stands at 40, indicating room for further selling before the stock becomes oversold. The year low of \u20ac30.25 is the last structural support; a break below that level could open the door to a multi-year decline.<\/p>\n

Novo Nordisk has tried to prop up its valuation with a DKK 15 billion share buyback programme. As of early June, it had repurchased roughly 18.76 million B-shares \u2013 a signal that management considers the current price cheap. So far the market disagrees, and the company\u2019s market capitalisation has shrunk to around \u20ac168 billion. The tug-of-war between strong clinical data and relentless competitive and pricing pressure remains unresolved, with investors counting down to the FDA\u2019s CagriSema verdict later this year.<\/p>\n

Ad<\/p>\n

Novo Nordisk Stock: New Analysis – 9 June<\/p>\n

Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n

Read our updated Novo Nordisk analysis…<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"While Novo Nordisk\u2019s pipeline continues to churn out clinical wins, its share price tells a far grimmer story.…\n","protected":false},"author":2,"featured_media":103850,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[52994,5401,6133,13583,3845,272,13590,45193,950,40944,1910],"class_list":["post-103849","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-cross","tag-death","tag-hits","tag-nordisks","tag-novo","tag-novo-nordisk","tag-oral","tag-scripts","tag-stock","tag-stuck","tag-wegovy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116721239073951552","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/103849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=103849"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/103849\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/103850"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=103849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=103849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=103849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}